本研究的目的是探讨多重肽脉冲自体树突状细胞（DC）联合细胞毒性T淋巴细胞（CTL）治疗癌症患者的安全性和有效性。 入组了2020年11月至2021年6月期间诊断为癌症的五名患者，接受 DC-CTL 治疗。收集外周血并分析抗原肽。采用流式细胞术或IFN-γ ELISPOT分析检测DC-CTL的表型和功能以及患者的免疫状态。共培养后DC获得成熟表型并表达高水平的CD80、CD86、CD83和HLA-DR DC-CTL 也表现出高水平的 IFN-γ。治疗后患者的外周血单核细胞对肽的免疫反应比治疗前更强。重要的是，五名患者中有四名保持了良好的免疫状态，其中一名患者的无病生存期长达28.2个月。未观察到严重的治疗相关不良事件。我们的结果表明，多重肽脉冲 DC 联合 CTL 治疗对癌症患者具有可控的安全性和良好的疗效，这可能为癌症提供精确的免疫治疗策略。版权所有 © 2023 赵，张，文、黄、杨、刘、耿、彭、李、张。

The aim of this study was to explore the safety and efficacy of multiple peptide-pulsed autologous dendritic cells (DCs) combined with cytotoxic T lymphocytes (CTLs) in patients with cancer.Five patients diagnosed with cancer between November 2020 and June 2021 were enrolled and received DC-CTLs therapy. Peripheral blood was collected and antigenic peptides were analyzed. The phenotype and function of DC-CTLs and the immune status of patients were detected using flow cytometry or IFN-γ ELISPOT analysis.DCs acquired a mature phenotype and expressed high levels of CD80, CD86, CD83, and HLA-DR after co-culture with peptides, and the DC-CTLs also exhibited high levels of IFN-γ. Peripheral blood mononuclear cells from post-treatment patients showed a stronger immune response to peptides than those prior to treatment. Importantly, four of five patients maintained a favorable immune status, of which one patient's disease-free survival lasted up to 28.2 months. No severe treatment-related adverse events were observed.Our results show that multiple peptide-pulsed DCs combined with CTLs therapy has manageable safety and promising efficacy for cancer patients, which might provide a precise immunotherapeutic strategy for cancer.Copyright © 2023 Zhao, Zhang, Wen, Huang, Yang, Liu, Geng, Peng, Li and Zhang.